このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Anteris Technologies 将来の成長

Future 基準チェック /06

Anteris Technologiesの収益と利益は、それぞれ年間2.7%と24.1%減少すると予測されています。EPS は年間3.2%で増加すると予想されています。自己資本利益率は 3 年後に-350.4%になると予測されています。

主要情報

-24.1%

収益成長率

3.2%

EPS成長率

Medical Equipment 収益成長	16.5%
収益成長率	-2.7%
将来の株主資本利益率	-350.4%
アナリストカバレッジ	Low
最終更新日	27 Sep 2024

今後の成長に関する最新情報

Recent updates

Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why

May 22

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Jul 08

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

May 07

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Feb 21

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

Dec 10

業績と収益の成長予測

ASX:AVR - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	4	-169	-165	-145	1
12/31/2025	5	-149	-140	-140	1
12/31/2024	6	-117	-95	-94	1
6/30/2024	4	-88	-73	-69	N/A
3/31/2024	4	-78	-64	-60	N/A
12/31/2023	4	-67	-55	-51	N/A
9/30/2023	4	-60	-50	-47	N/A
6/30/2023	4	-52	-45	-43	N/A
3/31/2023	5	-48	-43	-41	N/A
12/31/2022	5	-44	-40	-39	N/A
9/30/2022	6	-40	-37	-36	N/A
6/30/2022	7	-35	-34	-33	N/A
3/31/2022	7	-29	-27	-26	N/A
12/31/2021	8	-23	-20	-19	N/A
9/30/2021	7	-21	-16	-16	N/A
6/30/2021	6	-20	-12	-12	N/A
3/31/2021	7	-17	-13	-13	N/A
12/31/2020	7	-15	-14	-14	N/A
9/30/2020	9	-8	-6	-17	N/A
6/30/2020	10	0	2	-19	N/A
3/31/2020	14	-3	0	-21	N/A
12/31/2019	17	-6	-1	-23	N/A
9/30/2019	20	-15	-13	-24	N/A
6/30/2019	24	-24	-25	-24	N/A
3/31/2019	25	-24	-24	-23	N/A
12/31/2018	26	-24	-23	-22	N/A
12/31/2017	23	-17	N/A	-13	N/A
6/30/2017	22	-12	N/A	-12	N/A
3/31/2017	21	-15	N/A	-16	N/A
12/31/2016	20	-18	N/A	-20	N/A
9/30/2016	17	-21	N/A	-21	N/A
6/30/2016	14	-24	N/A	-22	N/A
3/31/2016	13	-26	N/A	-23	N/A
12/31/2015	12	-27	N/A	-24	N/A
9/30/2015	11	-26	N/A	-23	N/A
6/30/2015	10	-25	N/A	-21	N/A
3/31/2015	9	-21	N/A	-19	N/A
12/31/2014	9	-17	N/A	-17	N/A
9/30/2014	8	-12	N/A	-14	N/A
6/30/2014	8	-7	N/A	-11	N/A
3/31/2014	8	-4	N/A	-8	N/A
12/31/2013	8	-1	N/A	-6	N/A
9/30/2013	8	-1	N/A	-5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AVR今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: AVR今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: AVR今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: AVRの収益は今後 3 年間で減少すると予想されています (年間-2.7% )。

高い収益成長: AVRの収益は今後 3 年間で減少すると予測されています (年間-2.7% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AVR 3 年以内に赤字になると予測されています。

Anteris Technologies 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 12%, EPS downgraded

Recent updates

Consensus revenue estimates increase by 12%, EPS downgraded

Anteris Technologies SPONSORED ADR to Be Deleted from OTC Equity

First half 2024 earnings released: AU$2.75 loss per share (vs AU$2.01 loss in 1H 2023)

Anteris Technologies Ltd has filed a Follow-on Equity Offering in the amount of AUD 30 million.

Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study

Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why

Anteris Technologies Ltd, Annual General Meeting, May 29, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 40 million.

First half 2023 earnings released: AU$2.01 loss per share (vs AU$1.73 loss in 1H 2022)

Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case

Anteris Technologies Announces First Successful Implantation of Duravr™ Thv in A Valve-In-Valve Procedure

Full year 2022 earnings released: AU$3.32 loss per share (vs AU$3.09 loss in FY 2021)

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 35.000016 million.

Anteris Technologies Ltd announced that it expects to receive AUD 50 million in funding from Yorkville Advisors Global LP

Anteris Technologies Ltd Announces 12 Month Results for Anteris DurAVRTM Transcatheter Heart Valve Aortic Stenosis First in Human Study

Anteris Technologies Ltd Announces Formal Results of A Comparative Study to Investigate Aortic Flow Physiology by Cardiac MRI (cMRI) in Five Patients Who Received A DurAVR Transcatheter Aortic Valve (First- In-Human)

Anteris Technologies Ltd Announces Results Demonstrating Restoration of Normal Pre-Disease Flow

Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston

First half 2022 earnings released: EPS: AU$0 (vs AU$1.58 loss in 1H 2021)

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Anteris Technologies Ltd Provides Update on First In Human DurAVR THV Study

Anteris Announces 6 Month Follow Up of First Cohort of 5 Patients

Anteris Technologies Ltd Announces Successful Completion of Second First-In-Human Study

Anteris Technologies Ltd Announces Expansion of First in Human Trial

Anteris Technologies Ltd Appoints Dion Stub to Medical Advisory Board

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 27.6 million.

Anteris Technologies Ltd announced that it has received AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd announced that it expects to receive AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd, Annual General Meeting, May 19, 2022

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) cancelled the acquisition of Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Anteris Technologies Ltd Reports Successful Interim Results for the First-In-Human Trial

Anteris Technologies Ltd Reports New Patent Application for ADAPT

Independent Chairman of the Board exercised options to buy AU$58k worth of stock.

First half 2021 earnings released: AU$1.58 loss per share (vs AU$1.01 loss in 1H 2020)

Anteris Technologies Ltd announced that it has received AUD 9 million in funding

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Anteris Technologies Ltd Announces Successful Completion of Proof of Concept (Poc) Animal Study

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.327895 million.

Anteris Technologies Ltd announced that it expects to receive AUD 2.327895 million in funding

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

New 90-day high: AU$5.52

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Full year 2020 earnings released

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.171499 million.

New 90-day high: AU$4.30

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.068135 million.

Anteris Technologies Announces Resignation of Yanheng Wu as A Non-Executive Director on the Board

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

New 90-day low: AU$3.50

Anteris Technologies Ltd Reports Interim Results from Anti-Calcification Study

Anteris Technologies Limited Announces DurAVR Valve Patient Outcomes

First half earnings released

New 90-day low - AU$4.30

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘